Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

ObjectiveThe aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery.Materials and methodsA total of 109 patients with stage IIIA and IIIB NSCLC were prospectively genotyped to examine a potential association between XPD 312 (aspartic acid [Asp]/asparagine [Asn]), XPD 751 (lysine [Lys]/glutamine [Gln]), and RRM1 (-37 C/A) polymorphisms with response and survival.ResultsThe median survival was 32.14 months for carriers of XPD 312 Asp/Asp and 12.04 months for those with the variant Asn allele (P = .05). In addition, event-free survival was longer for patients with the XPD 312 Asp/Asp genotype compared with patients with Asp/Asn or Asn/Asn (P = .03). A similar but nonsignificant trend was observed for the XPD 751 genotype. In a multivariate analysis, complete resection and age emerged as prognostic factors for overall survival; in patients with incomplete resection or exploratory thoracotomy, XPD 312 was the most significant prognostic factor (P = .03).ConclusionThe XPD 312 single nucleotide polymorphism is a prognostic factor for survival in patients with locally advanced NSCLC receiving induction chemotherapy followed by surgery. The Asn allele is associated with unfavorable outcome and could be used for better stratification of patients.

Original publication

DOI

10.1016/j.cllc.2016.08.007

Type

Journal article

Journal

Clinical lung cancer

Publication Date

03/2017

Volume

18

Pages

178 - 188.e4

Addresses

Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy. Electronic address: c.santarpia@hotmail.com.

Keywords

Spanish Lung Cancer Group, Humans, Adenocarcinoma, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Cisplatin, Taxoids, Tumor Suppressor Proteins, Deoxycytidine, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Staging, Immunoenzyme Techniques, Prognosis, Combined Modality Therapy, Survival Rate, Follow-Up Studies, Prospective Studies, Genotype, Polymorphism, Single Nucleotide, Adult, Aged, Middle Aged, Female, Male, Xeroderma Pigmentosum Group D Protein, Induction Chemotherapy, Biomarkers, Tumor, Docetaxel